Re-engineering the target specificity of Clostridial neurotoxins - a route to novel therapeutics.
about
Botulinum neurotoxin devoid of receptor binding domain translocates active protease.Airway mucus function and dysfunction.Embryonic stem cell-derived motoneurons provide a highly sensitive cell culture model for botulinum neurotoxin studies, with implications for high-throughput drug discoveryTowards new uses of botulinum toxin as a novel therapeutic toolClinical uses of botulinum neurotoxins: current indications, limitations and future developmentsFuture aspects of botulinum neurotoxins.Botulinum neurotoxin: evolution from poison, to research tool--onto medicinal therapeutic and future pharmaceutical panacea.Engineering botulinum neurotoxin to extend therapeutic intervention.Botulinum toxin: future developments.Translocation of botulinum neurotoxin light chain protease by the heavy chain protein-conducting channelEvolution of neurotoxins: from research modalities to clinical realities.Botulinum neurotoxin for pain management: insights from animal models.Clostridial neurotoxins: mechanism of SNARE cleavage and outlook on potential substrate specificity reengineering.Botulinum protease-cleaved SNARE fragments induce cytotoxicity in neuroblastoma cells.Stapling of the botulinum type A protease to growth factors and neuropeptides allows selective targeting of neuroendocrine cellsStructural analysis of Clostridium botulinum neurotoxin type D as a platform for the development of targeted secretion inhibitors.Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes.Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics.Engineering Botulinum Toxins to Improve and Expand Targeting and SNARE Cleavage Activity
P2860
Q33394567-BB4E7B41-4D58-4C41-A49A-77FB538A4AA1Q33723578-76B950BB-BB82-4664-BC2B-4B1EA136A4F9Q34850583-7BE675FE-CB31-43E2-A59E-DE65CE90998BQ35534477-5BE3181B-8940-49F7-A64C-10E382865805Q36395728-59B33131-924E-4C94-8A93-8106D1A0F923Q36844148-EF5B3E64-5232-49EB-B67A-AF99DB343133Q37059470-8FDF5418-6C41-42E7-BACB-C8BA1A2B869CQ37224285-4EC17ABE-5956-4BD8-A809-9777FC092F3CQ37230033-BF4F737E-C630-457C-9DF7-410712AB909AQ37359166-898230FD-F5CA-4C63-A6C1-0293FECC576EQ37377735-2968F922-5E05-4CC3-AA15-C367D2D454ECQ37954278-2B8E333B-3D88-417D-A58A-9B2AAE285BCEQ37954285-271AE0E9-CBCF-40C6-A15E-92149BDA00E3Q39039170-185B5243-06CC-4D73-AB04-88923A2F6F77Q39157207-0D31B429-FBEF-411A-9A49-4ACB976E01CCQ42580273-31299EEC-1142-424F-9729-8BC587F95207Q43097051-19CB653F-20AF-4DD5-BC6E-85BE38136467Q47783055-9C224A69-B108-4D75-AE61-ABC8AD48BEE8Q57177243-5739AB9B-4DA0-410D-A89F-721D337DDED7
P2860
Re-engineering the target specificity of Clostridial neurotoxins - a route to novel therapeutics.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Re-engineering the target spec ...... a route to novel therapeutics.
@en
type
label
Re-engineering the target spec ...... a route to novel therapeutics.
@en
prefLabel
Re-engineering the target spec ...... a route to novel therapeutics.
@en
P2093
P2860
P356
P1476
Re-engineering the target spec ...... a route to novel therapeutics.
@en
P2093
C J Cruttwell
D F Rogers
F C G Alexander
J A Chaddock
J M Sutton
P2860
P2888
P304
P356
10.1007/BF03354881
P577
2006-04-01T00:00:00Z